News | February 25, 2026
Formosa strikes exclusive deal with Arrotex to launch eye surgery drug in Australia & NZ
The innovative eyedrop targets inflammation and pain following ocular surgery
The innovative eyedrop targets inflammation and pain following ocular surgery
The Phase 2 trial, conducted through Starton’s Sargon Site Network, is expanding from two to six sites across the U.S.
The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform
The MoU lays the groundwork for deep academic and research collaboration in pharmaceutical technologies
One of India’s top integrated contract research, development, and manufacturing organizations (CRDMOs) is on a hiring spree
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
The new lineup features everything from the Color Fixation and Hair Therapy ranges to the Balanced Cleansing Shampoo and Nourishment & Protection Conditioner
The alliance directly links VivaMed’s computational drug hypotheses with Syngene’s preclinical development capabilities
Merck is currently conducting approximately 80 Phase 3 studies, and the company expects more than 20 new growth drivers over next several years, almost all with blockbuster potential
Subscribe To Our Newsletter & Stay Updated
